Joh T, Takezono Y, Oshima T, Sasaki M, Seno K, Yokoyama Y, Ohara H, Nomura T, Alexander J S, Itoh M
Department of Internal Medicine & Bioregulation, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Aliment Pharmacol Ther. 2003 Jul;18 Suppl 1:133-8. doi: 10.1046/j.1365-2036.18.s1.15.x.
Barrier function in gastric epithelial cells is essential for the gastric defence mechanism against acid back-diffusion into the mucosal layer. Our previous study indicated that trans-epithelial resistance (TER) of rat gastric epithelial cells was rapidly increased when the cells were exposed to acid. This response to acid was diminished by indometacin.
Evaluate the effects of a mucoprotective agent, rebamipide, on the nonsteroidal anti-inflammatory drug (NSAID)-induced increase of gastric epithelial permeability.
Rat gastric epithelial cells were plated on tissue culture inserts. Cells were exposed to a NSAID (indometacin, 10-7 M). Trans-epithelial permeability was measured by TER and diffusion rate of 14C-mannitol. The effect of rebamipide was evaluated by measuring TER. Endogenous prostaglandin E2 (PGE2) production in culture medium was also measured.
Indometacin gradually and significantly decreased TER and increased 14C-manitol permeability. Rebamipide reversed the indometacin-induced changes in epithelial permeability and induced PGE2 synthesis. This induction was blocked by either indometacin or a Cyclooxygenase (COX)-2 specific inhibitor.
COX inhibitors such as indometacin inhibit regulation of epithelial permeability by reducing PGE2. COX-1 has an important role in the gastric defense mechanism. Rebamipide suppressed an indometacin-induced increase in gastric epithelial permeability by increasing PGE2 levels in a COX-2 dependent manner.
胃上皮细胞的屏障功能对于胃抵御酸反向扩散至黏膜层的防御机制至关重要。我们之前的研究表明,当大鼠胃上皮细胞暴露于酸时,其跨上皮电阻(TER)会迅速增加。吲哚美辛会减弱这种对酸的反应。
评估黏膜保护剂瑞巴派特对非甾体抗炎药(NSAID)诱导的胃上皮通透性增加的影响。
将大鼠胃上皮细胞接种于组织培养插入物上。细胞暴露于一种NSAID(吲哚美辛,10 -7 M)。通过TER和14C-甘露醇的扩散速率来测量跨上皮通透性。通过测量TER来评估瑞巴派特的作用。还测量了培养基中内源性前列腺素E2(PGE2)的产生。
吲哚美辛逐渐且显著降低TER并增加14C-甘露醇通透性。瑞巴派特逆转了吲哚美辛诱导的上皮通透性变化并诱导PGE2合成。这种诱导被吲哚美辛或环氧化酶(COX)-2特异性抑制剂阻断。
吲哚美辛等COX抑制剂通过降低PGE2来抑制上皮通透性的调节。COX-1在胃防御机制中起重要作用。瑞巴派特通过以COX-2依赖的方式增加PGE2水平来抑制吲哚美辛诱导的胃上皮通透性增加。